Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | PLA2G7 | Q13093 | 8/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL875895 | 1.00 | POLB (0.43) | POLBALDH1A1L3MBTL1KDM4EPLA2G7 | |
| SCHEMBL875480 | 0.83 | ALDH1A1 (0.62) | POLBALDH1A1L3MBTL1KDM4EPLA2G7 | |
| SCHEMBL16199421 | 0.82 | KDM4E (0.41) | POLBALDH1A1L3MBTL1KDM4ETHRB | |
| SCHEMBL875436 | 0.76 | POLB (0.44) | POLBALDH1A1L3MBTL1KDM4EPLA2G7 | |
| SCHEMBL875076 | 0.76 | PLA2G7 (0.44) | POLBKDM4EPLA2G7BRAFKDR | |
| SCHEMBL875590 | 0.74 | PLA2G7 (0.43) | POLBKDM4EPLA2G7BRAFKDR | |
| SCHEMBL15195551 | 0.74 | KDM4E (0.47) | POLBALDH1A1L3MBTL1KDM4EPLA2G7 | |
| SCHEMBL7885604 | 0.71 | RAF1 (0.49) | PLA2G7BRAFKDR | |
| SCHEMBL3457827 | 0.71 | CDK8 (0.49) | POLBALDH1A1KDM4EPLA2G7BRAF | |
| SCHEMBL1201822 | 0.71 | KDM4E (0.50) | POLBALDH1A1KDM4EPLA2G7BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140378487-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LTD (GB) | 2014-12-25 | — | — | US | disclosed |
| US-20140378487-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LTD (GB) | 2014-12-25 | — | — | US | disclosed |
| US-8871928-B2 | Tricyclic compounds, preparation methods, and their uses | GLAXO GROUP LIMITED (GB) | 2014-10-28 | — | — | US | disclosed |
| EP-2619203-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | Glaxo Group Limited (GB) | 2013-07-31 | — | — | EP | disclosed |
| US-20130178488-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LIMITED (GB) | 2013-07-11 | — | — | US | disclosed |
| WO-2012037782-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LIMITED (GB) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012037782-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LIMITED (GB) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378487-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | LIPG, PCSK9, ENPP2 | POLB 1644/4885ALDH1A1 3675/4885L3MBTL1 3983/4885 |
| US-20130178488-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | LIPG, PCSK9, ENPP2 | POLB 1644/4885ALDH1A1 3675/4885L3MBTL1 3983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.